The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30 mg oxazepam

British Journal of Clinical Pharmacology

Volumn 66, Issue 4, 2008, Pages 556-560

  Smink, Beitske E ^a   Hofman, Berendina J A ^a,e   Dijkhuizen, Albert ^a   Lusthof, Klaas J ^a   De Gier, Johan J ^b   Egberts, Antoine C G ^c,d   Uges, Donald R A ^e  

^a NETHERLANDS FORENSIC INSTITUTE   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Oral fluid; Oxazepam; Oxazepam glucuronide; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; OXAZEPAM; OXAZEPAM GLUCURONIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG GLUCURONIDATION; DRUG SALIVA LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DRUG ADMINISTRATION ROUTES; HUMANS; HYPNOTICS AND SEDATIVES; MALE; OXAZEPAM; PREDICTIVE VALUE OF TESTS; SALIVA; SERUM; SUBSTANCE ABUSE DETECTION; TREATMENT OUTCOME;

EID: 51649103137     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03252.x     Document Type: Article

References (10)

1. Kelly E, Darke S, Ross J. A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev 2004 23: 319 44.
2. Movig KL, Mathijssen MP, Nagel PH, van Egmond T, de Gier JJ, Leufkens HGM, Egberts ACG. Psychoactive substance use and the risk of motor vehicle accidents. Accid Anal Prev 2004 36: 631 6.
3. Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992 22: 155 63.
4. Sonne J, Loft S, Dossing M, Vollmer-Larsen A, Olesen KL, Victor M, Andreasen F, Andreasen PB. Bioavailability and pharmacokinetics of oxazepam. Eur J Clin Pharmacol 1988 35: 385 9.
5. Glatting G, Kletting P, Reske SN. Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test. Med Phys 2007 34: 4285 92.
6. Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther 1980 215: 86 91.
7. Ochs HR, Greenblatt DJ, Otten H. Disposition of oxazepam in relation to age, sex, and cigarette smoking. Klin Wochenschr 1981 59: 899 903.
8. Sonne J. Factors and conditions affecting the glucuronidation of oxazepam. Pharmacol Toxicol 1993 73 (Suppl. 1 1 23.
9. Shull HJ, Wilkinson GR, Johnson R, Schenker S. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern.Med 1976 84: 420 5.
10. Oxazepam. In: Clarke's Analysis of Drugs and Poisons, eds Moffat AC, Osselton MD, Widdop B. London, Chicago: Pharmaceutical Press, 2004 1375 6.